Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00041990 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
A Phase 2 study of Chronic Myelogenous Leukemia, sponsored by Astex Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 8
- Study locations
NCT00041990: Completed Phase 2 study of Chronic Myelogenous Leukemia, sponsored by Astex Pharmaceuticals.
NCT00041990 is a Phase 2 study of Chronic Myelogenous Leukemia that has completed, run by Astex Pharmaceuticals. The registered enrollment target is 40 participants, below the 281-participant average among 29 other Chronic Myelogenous Leukemia trials with a reported enrollment target (86% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00041990, a Phase 2 study of Chronic Myelogenous Leukemia, has completed, sponsored by Astex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 8
- Study locations
Study Summary
To determine the safety and efficacy of decitabine in patients with Philadelphia chromosome-positive chronic myelogenous leukemia accelerated phase that were previously treated with imatinib mesylate (STI 571) and became resistant/refractory or were found to be intolerant to the drug.
Conditions Studied
Interventions
- DRUG decitabine (5-aza-2'deoxycytidine)
Study Locations (8)
California
- City of Hope Medical Center - Duarte
- Scripps Clinic - Escondido
- USC/Norris Cancer Center - Los Angeles
Minnesota
- Metro-Minnesota CCOP - Saint Louis Park
New York
- New York Medical College - Valhalla
South Carolina
- Liberty Hematology/Oncology - Columbia
Texas
- University of Texas MD Anderson Cancer Center - Houston
Ontario
- Princess Margaret Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2002-07 |
| Phase | Phase 2 |
What the finished NCT00041990 record still lists
NCT00041990 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 281-participant average among 29 other Chronic Myelogenous Leukemia trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Chronic Myelogenous Leukemia appearing as the primary indexed condition, and to 1 intervention - of which decitabine (5-aza-2'deoxycytidine) is the first listed.
NCT00041990 lists 8 locations in 6 states (California, Minnesota, New York).
Frequently Asked Questions
What is clinical trial NCT00041990 about?
NCT00041990 is a clinical study titled "Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)". To determine the safety and efficacy of decitabine in patients with Philadelphia chromosome-positive chronic myelogenous leukemia accelerated phase that were previously treated with imatinib mesylate (STI 571) and became resistant/refractory or were found to be intolerant to the drug.
What is the current status of trial NCT00041990?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2002-07.
What conditions does trial NCT00041990 study?
This clinical trial studies the following conditions: Chronic Myelogenous Leukemia.
What interventions are being tested in trial NCT00041990?
The interventions under investigation include: decitabine (5-aza-2'deoxycytidine) (DRUG).
Who is sponsoring clinical trial NCT00041990?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00041990 being conducted?
This trial has 8 study locations across California, Minnesota, New York, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myelogenous Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00041990's enrollment target sits among peer trials
40 21st of 29 higher than 9 of 29 other Chronic Myelogenous Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Myelogenous Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
RECRUITING · Phase 2
-
Allo HSCT Using RIC and PTCy for Hematological Diseases
RECRUITING · Phase 2
-
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
ACTIVE NOT RECRUITING · Phase 2
-
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
ACTIVE NOT RECRUITING · Phase 2
-
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia